178 related articles for article (PubMed ID: 23272809)
21. Serum and tissue CTACK/CCL27 chemokine levels in early mycosis fungoides may be correlated with disease-free survival following treatment with interferon alfa and psoralen plus ultraviolet A therapy.
Goteri G; Rupoli S; Campanati A; Zizzi A; Picardi P; Cardelli M; Giantomassi F; Canafoglia L; Marchegiani F; Mozzicafreddo G; Brandozzi G; Stramazzotti D; Ganzetti G; Lisa R; Simonetti O; Offidani A; Federici I; Filosa G; Leoni P
Br J Dermatol; 2012 May; 166(5):948-52. PubMed ID: 22233400
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and safety of interferon α-2a combined with phototherapy for patients with early-stage mycosis fungoides - a single-arm prospective study in 13 patients.
Song H; Hu Z; Zhang S; Yang L; Feng J; Lu L; Liu Y; Wang T
J Dermatolog Treat; 2024 Dec; 35(1):2350231. PubMed ID: 38754985
[No Abstract] [Full Text] [Related]
23. Interferon-alpha is effective for CD4(+), CCR4(-) mycosis fungoides.
Fujimura T; Okuyama R; Watabe A; Hashimoto A; Tagami H; Aiba S
Int J Dermatol; 2007 Apr; 46(4):435-8. PubMed ID: 17442093
[TBL] [Abstract][Full Text] [Related]
24. Recombinant interferon-alpha2b poly(lactic-co-glycolic acid) microspheres: pharmacokinetics-pharmacodynamics study in rhesus monkeys following intramuscular administration.
Zhang YM; Yang F; Yang YQ; Song FL; Xu AL
Acta Pharmacol Sin; 2008 Nov; 29(11):1370-5. PubMed ID: 18954532
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa.
Jumbou O; N'Guyen JM; Tessier MH; Legoux B; Dréno B
Br J Dermatol; 1999 Mar; 140(3):427-31. PubMed ID: 10233261
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
Yamazaki N; Uhara H; Wada H; Matsuda K; Yamamoto K; Shimamoto T; Kiyohara Y
J Dermatol; 2016 Oct; 43(10):1146-1153. PubMed ID: 27087489
[TBL] [Abstract][Full Text] [Related]
27. Changes of serum neopterin, beta 2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b.
Fuchs D; Norkrans G; Wejstal R; Reibnegger G; Weiss G; Weiland O; Schvarcz R; Fryden A; Wachter H
Eur J Med; 1992; 1(4):196-200. PubMed ID: 1341444
[TBL] [Abstract][Full Text] [Related]
28. Interferon-based treatment for patients with mycosis fungoides and hepatitis C virus infection: a case series.
Kyvernitakis A; Duvic M; Mahale P; Torres HA
Am J Clin Dermatol; 2014 Oct; 15(5):451-6. PubMed ID: 24934807
[TBL] [Abstract][Full Text] [Related]
29. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
Schiller JH; Storer B; Paulnock DM; Brown RR; Datta SP; Witt PL; Borden EC
J Clin Invest; 1990 Oct; 86(4):1211-21. PubMed ID: 2120284
[TBL] [Abstract][Full Text] [Related]
30. Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model.
Jeon S; Juhn JH; Han S; Lee J; Hong T; Paek J; Yim DS
J Transl Med; 2013 Oct; 11():240. PubMed ID: 24088361
[TBL] [Abstract][Full Text] [Related]
31. Assessment of the safety, tolerability, and PK/PD properties of two new formulations of subcutaneously administered IFN-beta1a: a double-blind, placebo-controlled comparison with the currently available formulation.
Brearley C; Jaber A; Bertolino M; Priestley A; Seiberling M
Int J Clin Pharmacol Ther; 2007 Jun; 45(6):307-18. PubMed ID: 17595888
[TBL] [Abstract][Full Text] [Related]
32. Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study.
Bruno R; Sacchi P; Scagnolari C; Torriani F; Maiocchi L; Patruno S; Bellomi F; Filice G; Antonelli G
Aliment Pharmacol Ther; 2007 Aug; 26(3):369-76. PubMed ID: 17635371
[TBL] [Abstract][Full Text] [Related]
33. Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.
Foster GR
Expert Opin Pharmacother; 2003 May; 4(5):685-91. PubMed ID: 12739994
[TBL] [Abstract][Full Text] [Related]
34. Cytokine profile of tumor cells in mycosis fungoides: successful treatment with intra-lesional interferon-gamma combined with chemotherapy.
Yamamoto T; Sasaki G; Sato T; Katayama I; Nishioka K
J Dermatol; 1995 Sep; 22(9):650-4. PubMed ID: 8537550
[TBL] [Abstract][Full Text] [Related]
35. Treatment with human gamma interferon of chronic hepatitis B: comparative study with alpha interferon.
Kakumu S; Ishikawa T; Mizokami M; Orido E; Yoshioka K; Wakita T; Yamamoto M
J Med Virol; 1991 Sep; 35(1):32-7. PubMed ID: 1940881
[TBL] [Abstract][Full Text] [Related]
36. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
Couzigou P; Pérusat S; Bourlière M; Trimoulet P; Poynard T; Leroy V; Marcellin P; Foucher J; Bronowicki JP; Chêne G;
J Gastroenterol Hepatol; 2013 Feb; 28(2):329-34. PubMed ID: 23190183
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo.
Davis-Daneshfar A; Böni R; von Wussow P; Joller H; Burg G; Dummer R
J Immunother; 1997 May; 20(3):208-13. PubMed ID: 9181459
[TBL] [Abstract][Full Text] [Related]
38. Interferon in the treatment of cutaneous T-cell lymphoma.
Olsen EA
Dermatol Ther; 2003; 16(4):311-21. PubMed ID: 14686974
[TBL] [Abstract][Full Text] [Related]
39. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
40. In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a.
Hu X; Olivier K; Polack E; Crossman M; Zokowski K; Gronke RS; Parker S; Li Z; Nestorov I; Baker DP; Clarke J; Subramanyam M
J Pharmacol Exp Ther; 2011 Sep; 338(3):984-96. PubMed ID: 21690216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
